Familial Hemophagocytic Lymphohistiocytosis (FHL) Panel
Use
The Familial Hemophagocytic Lymphohistiocytosis (FHL) Panel is designed for individuals with relevant features who have a clinical or suspected diagnosis of FHL, as well as males with suspected X-linked lymphoproliferative disorder. This comprehensive 29-gene panel helps in diagnosing and managing FHL, a severe systemic inflammatory condition caused by inherited or acquired forms, to guide therapeutic and preventive interventions.
Special Instructions
Not provided.
Limitations
The panel does not cover all genetic variations associated with hemophagocytic lymphohistiocytosis, and rare or unknown mutations may not be detected. Accuracy of results can be affected by the quality of the specimen and completeness of clinical information provided. Tests are not cleared or approved by the US FDA, though they are performed in a CAP-accredited and CLIA-certified lab.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
No genes
Gene
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided